Lista de obras -

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

artículo científico publicado en 2009

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

artículo científico publicado en 2015

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

artículo científico publicado en 2015

ACTR-76. FINAL RESULTS FROM A PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2017

AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2014

ATNT-14PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

artículo científico publicado en 2015

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

artículo científico publicado en 2007

Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas

artículo científico publicado en 2008

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

artículo científico publicado en 2016

Angiogenesis as a therapeutic target in malignant gliomas

artículo científico publicado en 2009

Angiogenesis in brain tumours

artículo científico publicado en 2007

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy

artículo científico publicado en 2016

Anti-vascular endothelial growth factor therapy for malignant glioma

artículo científico publicado en 2009

Antiangiogenic agents for the treatment of glioblastoma

scientific article published on December 2007

Antiangiogenic therapy for glioblastoma: current status and future prospects

artículo científico publicado en 2014

BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma

artículo científico publicado en 2012

Biomarkers of response and resistance to antiangiogenic therapy

artículo científico publicado en 2009

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

scientific article published on 04 February 2019

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

artículo científico publicado en 2016

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

artículo científico publicado en 2017

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

artículo científico publicado en 2009

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

scientific article published on 08 June 2020

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

artículo científico publicado en 2015

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

artículo científico publicado en 2020

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas

artículo científico publicado en 2016

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

artículo científico publicado en 2011

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

artículo científico publicado en 2013

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

scientific article published on 04 July 2013

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

artículo científico publicado en 2011

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

artículo científico publicado en 2010

L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas

scientific article published on 01 February 2019

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

artículo científico publicado en 2015

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation

artículo científico publicado en 2013

Mechanisms and therapeutic implications of hypermutation in gliomas

artículo científico publicado en 2020

NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

New Directions in Anti-Angiogenic Therapy for Glioblastoma

artículo científico publicado en 2017

ONGOING CLINICAL TRIALS

article

PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM.

artículo científico publicado en 2014

Pathway inhibition: emerging molecular targets for treating glioblastoma

artículo científico publicado en 2011

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

artículo científico publicado en 2013

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.

artículo científico publicado en 2018

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

artículo científico publicado en 2011

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide ⬇️

artículo científico publicado el 7 de septiembre de 2010

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

artículo científico publicado en 2010

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

artículo científico publicado en 2014

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

artículo científico publicado en 2015

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

artículo científico publicado en 2016

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

artículo científico publicado en 2013

Primary central nervous system lymphoma

artículo científico publicado en 2018

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

artículo científico publicado en 2018

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

artículo científico publicado en 2020

Reply to B. Freidlin et al.

artículo científico publicado en 2013

Response criteria for glioma

artículo científico publicado en 2008

Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma ⬇️

artículo científico publicado el 20 de abril de 2011

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

artículo científico publicado en 2020

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium

scientific article published on 07 January 2019

Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas

scientific article published on 07 January 2020

T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients

artículo científico publicado en 2011

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

artículo científico publicado en 2009

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

artículo científico publicado en 2007

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

scientific article published on 18 August 2013

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

artículo científico publicado en 2014

cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification

artículo científico publicado en 2016

Lista de obras de

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

ACTR-76. FINAL RESULTS FROM A PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA

AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

ATNT-14PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

Angiogenesis as a therapeutic target in malignant gliomas

Angiogenesis in brain tumours

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy

Anti-vascular endothelial growth factor therapy for malignant glioma

Antiangiogenic agents for the treatment of glioblastoma

Antiangiogenic therapy for glioblastoma: current status and future prospects

BM-07GENOMIC CHARACTERIZATION OF BRAIN METASTASES REVEALS BRANCHED EVOLUTION AND METASTASIS-SPECIFIC MUTATIONS

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma

Biomarkers of response and resistance to antiangiogenic therapy

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation

Mechanisms and therapeutic implications of hypermutation in gliomas

NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE

New Directions in Anti-Angiogenic Therapy for Glioblastoma

ONGOING CLINICAL TRIALS

PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM.

Pathway inhibition: emerging molecular targets for treating glioblastoma

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma

Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide ⬇️

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Primary central nervous system lymphoma

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Reply to B. Freidlin et al.

Response criteria for glioma

Serial Magnetic Resonance Spectroscopy Reveals a Direct Metabolic Effect of Cediranib in Glioblastoma ⬇️

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium

Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas

T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification